Table 3.
Two-year clinical outcomes according to the different glycemic status.
| Outcomes | 1G-DES | ||||||
|---|---|---|---|---|---|---|---|
| Group A1 normoglycemia (n = 482) | Group B1 prediabetes (n = 767) | Log-rank | Unadjusted | Adjusteda | |||
| HR (95% CI) | p value | HR (95% CI) | p value | ||||
| POCOs | 41 (8.6) | 91 (12.0) | 0.072 | 1.400 (1.968–2.024) | 0.074 | 1.483 (0.985–2.232) | 0.059 |
| All-cause death | 22 (4.6) | 43 (5.6) | 0.422 | 1.234 (0.738–2.062) | 0.423 | 1.227 (0.675–2.033) | 0.502 |
| Cardiac death | 17 (3.6) | 34 (4.5) | 0.433 | 1.261 (0.705–2.257) | 0.435 | 1.455 (0.721–2.935) | 0.295 |
| Re-MI | 8 (1.7) | 19 (2.5) | 0.334 | 1.498 (0.656–3.422) | 0.337 | 1.748 (0.685–4.464) | 0.243 |
| All-cause death or MI | 27 (5.6) | 52 (6.8) | 0.412 | 1.215 (0.763–1.933) | 0.413 | 1.194 (0.707–1.919) | 0.507 |
| Any repeat revascularization | 17 (3.6) | 46 (6.3) | 0.053 | 1.719 (0.986–2.999) | 0.056 | 1.858 (1.027–3.359) | 0.040 |
| ST (probable or definite) | 7 (1.5) | 14 (1.8) | 0.642 | 1.259 (0.508–3.119) | 0.619 | 1.346 (0.511–3.547) | 0.548 |
| Outcomes | Group A1 Normoglycemia (n = 482) | Group C1 diabetes (n = 779) | Log-rank | Unadjusted | Adjusteda | ||
|---|---|---|---|---|---|---|---|
| HR (95% CI) | p value | HR (95% CI) | p value | ||||
| POCOs | 41 (8.6) | 107 (13.9) | 0.007 | 1.630 (1.137–2.336) | 0.008 | 1.667 (1.105–2.515) | 0.015 |
| All-cause death | 22 (4.6) | 50 (6.5) | 0.168 | 1.420 (0.860–2.345) | 0.170 | 1.451 (0.797–2.639) | 0.164 |
| Cardiac death | 17 (3.6) | 42 (5.4) | 0.130 | 1.540 (0.877–2.705) | 0.133 | 1.652 (0.815–3.349) | 0.129 |
| Re-MI | 8 (1.7) | 24 (3.2) | 0.118 | 1.873 (0.841–4.169) | 0.124 | 2.500 (0.971–6.441) | 0.058 |
| All-cause death or MI | 27 (5.6) | 64 (8.3) | 0.084 | 1.483 (0.946–2.325) | 0.086 | 1.496 (0.885–2.531) | 0.072 |
| Any repeat revascularization | 17 (3.6) | 51 (6.9) | 0.022 | 1.878 (1.084–3.251) | 0.024 | 1.875 (1.029–3.215) | 0.038 |
| ST (probable or definite) | 7 (1.5) | 16 (2.1) | 0.642 | 1.240 (0.500–3.071) | 0.643 | 1.539 (0.580–4.084) | 0.386 |
| Outcomes | Group B1 Prediabetes (n = 767) |
Group C1 Diabetes (n = 779) |
Log-rank | Unadjusted | Adjusteda | ||
|---|---|---|---|---|---|---|---|
| HR (95% CI) | p value | HR (95% CI) | p value | ||||
| POCOs | 91 (12.0) | 107 (13.9) | 0.285 | 1.165 (0.881–1.540) | 0.285 | 1.135 (0.836–1.535) | 0.417 |
| All-cause death | 43 (5.6) | 50 (6.5) | 0.500 | 1.151 (0.765–1.730) | 0.500 | 1.166 (0.731–1.860) | 0.488 |
| Cardiac death | 34 (4.5) | 42 (5.4) | 0.385 | 1.221 (0.777–1.919) | 0.386 | 1.137 (0.678–1.909) | 0.627 |
| Re-MI | 19 (2.5) | 24 (3.2) | 0.462 | 1.253 (0.686–2.287) | 0.463 | 1.148 (0.599–2.199) | 0.678 |
| All-cause death or MI | 52 (6.8) | 64 (8.3) | 0.283 | 1.221 (0.847–1.761) | 0.284 | 1.189 (0.788–1.757) | 0.410 |
| Any repeat revascularization | 46 (6.3) | 51 (6.9) | 0.663 | 1.093 (0.733–1.627) | 0.663 | 1.035 (0.681–1.574) | 0.872 |
| ST (probable or definite) | 14 (1.8) | 16 (2.1) | 0.969 | 1.015 (0.484–2.128) | 0.969 | 1.175 (0.551–2.507) | 0.677 |
| Outcomes | 2G-DES | ||||||
|---|---|---|---|---|---|---|---|
| Group A2 Normoglycemia (n = 3191) |
Group B2 Prediabetes (n = 4438) |
Log-rank | Unadjusted | Adjustedb | |||
| HR (95% CI) | p value | HR (95% CI) | p value | ||||
| POCOs | 193 (6.7) | 371 (8.9) | < 0.001 | 1.388 (1.167–1.650) | < 0.001 | 1.294 (1.078–1.553) | 0.006 |
| All-cause death | 80 (2.7) | 185 (4.4) | < 0.001 | 1.642 (1.263–2.134) | < 0.001 | 1.353 (1.021–1.793) | 0.035 |
| Cardiac death | 59 (1.9) | 140 (3.3) | 0.001 | 1.693 (1.249–2.295) | 0.001 | 1.392 (1.004–1.930) | 0.047 |
| Re-MI | 42 (1.5) | 80 (2.0) | 0.121 | 1.342 (0.924–1.950) | 0.122 | 1.288 (0.876–1.894) | 0.198 |
| All-cause death or MI | 116 (4.0) | 258 (6.1) | < 0.001 | 1.578 (1.268–1.965) | < 0.001 | 1.425 (1.132–1.794) | 0.003 |
| Any repeat revascularization | 85 (3.1) | 144 (3.6) | 0.206 | 1.189 (0.909–1.554) | 0.206 | 1.223 (0.923–1.619) | 0.161 |
| ST (probable or definite) | 15 (0.5) | 29 (0.7) | 0.296 | 1.392 (0.746–2.597) | 0.298 | 1.520 (0.787–2.937) | 0.213 |
| Outcomes | Group A2 Normoglycemia (n = 3191) |
Group C2 Diabetes (n = 4238) |
Log-rank | Unadjusted | Adjustedb | ||
|---|---|---|---|---|---|---|---|
| HR (95% CI) | p value | HR (95% CI) | p value | ||||
| POCOs | 193 (6.7) | 410 (10.3) | < 0.001 | 1.566 (1.320–1.859) | < 0.001 | 1.400 (1.165–1.683) | < 0.001 |
| All-cause death | 80 (2.7) | 189 (4.7) | < 0.001 | 1.748 (1.346–2.271) | < 0.001 | 1.430 (1.074–1.095) | 0.014 |
| Cardiac death | 59 (1.9) | 144 (3.5) | < 0.001 | 1.815 (1.341–2.457) | < 0.001 | 1.471 (1.055–2.052) | 0.023 |
| Re-MI | 42 (1.5) | 105 (2.8) | 0.001 | 1.829 (1.278–2.616) | 0.001 | 1.694 (1.161–2.472) | 0.006 |
| All-cause death or MI | 116 (4.0) | 296 (7.4) | < 0.001 | 1.885 (1.521–2.336) | < 0.001 | 1.684 (1.338–2.120) | < 0.001 |
| Any repeat revascularization | 85 (3.1) | 160 (4.3) | 0.018 | 1.370 (1.053–1.783) | 0.019 | 1.362 (1.031–1.769) | 0.030 |
| ST (probable or definite) | 15 (0.5) | 40 (0.9) | 0.018 | 2.012 (1.112–3.642) | 0.021 | 2.068 (1.125–3.869) | 0.014 |
| Outcomes | Group B2 Prediabetes (n = 4438) |
Group C2 Diabetes (n = 4238) |
Log-rank | Unadjusted | Adjustedb | ||
|---|---|---|---|---|---|---|---|
| HR (95% CI) | p value | HR (95% CI) | p value | ||||
| POCOs | 371 (8.9) | 410 (10.3) | 0.046 | 1.153 (1.002–1.327) | 0.046 | 1.116 (0.962–1.294) | 0.148 |
| All-cause death | 185 (4.4) | 189 (4.7) | 0.531 | 1.067 (0.871–1.307) | 0.531 | 1.109 (0.887–1.386) | 0.365 |
| Cardiac death | 140 (3.3) | 144 (3.5) | 0.543 | 1.075 (0.852–1.356) | 0.544 | 1.062 (0.822–1.334) | 0.644 |
| Re-MI | 80 (2.0) | 105 (2.8) | 0.036 | 1.368 (1.022–1.829) | 0.035 | 1.393 (1.135–2.043) | 0.032 |
| All-cause death or MI | 258 (6.1) | 296 (7.4) | 0.033 | 1.197 (1.013–1.415) | 0.034 | 1.224 (1.023–1.524) | 0.029 |
| Any repeat revascularization | 144 (3.6) | 160 (4.3) | 0.203 | 1.157 (0.924–1.449) | 0.204 | 1.088 (0.863–1.373) | 0.474 |
| ST (definite or probable) | 29 (0.7) | 40 (0.9) | 0.129 | 1.445 (0.896–2.331) | 0.131 | 1.546 (0.942–2.538) | 0.085 |
POCOs patient-oriented composite outcomes defined as a composite of all-cause deaths, Re-MI or any repeat revascularization, Re-MI recurrent myocardial infarction, LVEF left ventricular ejection fraction, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, MI myocardial infarction, PCI percutaneous coronary intervention, CABG coronary artery bypass graft, HF heart failure, CVA cerebrovascular accidents, CK-MB creatine kinase myocardial band, NT-ProBNP N-terminal pro-brain natriuretic peptide, HDL high-density lipoprotein, LDL low-density lipoprotein, ACEIs angiotensin converting enzyme inhibitors, ARBs angiotensin receptor blockers, CCBs calcium channel blockers, IRA infarct-related artery, RCA right coronary artery, ACC/AHA American College of Cardiology/American Heart Association, FFR fractional flow reserve.
aAdjusted by male, age, LVEF, BMI, cardiogenic shock, hypertension, dyslipidemia, previous HF, current smoker, CK-MB, ACEIs, 1-vessel, ≥ 3-vessel disease, triglyceride, stent diameter (p vales of these covariates were < 0.005 or having predictive values).
bAdjusted by male, age, LVEF, BMI, DBP, STEMI, hypertension, dyslipidemia, previous MI, previous PCI, previous CVA, CK-MB, serum creatinine, total cholesterol, triglyceride, HDL-cholesterol, LDL-cholesterol, clopidogrel, ticagrelor, cilostazole, ACEIs, ARBs, CCB, lipid lowering agents, RCA (treated vessel), 1-vessel disease, ≥ 3-vessel disease, stent diameter, number of stent (p vales of these covariates were < 0.001 or having predictive values).